

MARCH 16-17 2021

**IMMUNOLOGY
& INFLAMMATORY
DISORDERS**

START-UP

100% DIGITAL EXPERIENCE

WWW.HYBRIDAYS.COM

Table of contents

Encefa	03
Enterome	05
Exeliom Biosciences	09
Immune Insight	13
Inotrem	19
LiMM	21
MaaT Pharma	25
Medsenic	28
OSE Immunotherapeutics	31
Par'Immune	33
Peptinov	36
Stimulab	39

Activity

Pre-clinical biotech company developing First-in-Class antibodies against a wide range of inflammaging/ age-related diseases, by activating directly both:

- (1) the Autophagy-Lysosomal Flux (up to lysosomal exocytosis), and
- (2) the Energy Metabolism (insulin-independent glucose uptake) of CD38+ cells.

CD38 is an age-related target known to be a marker of pro-inflammation and linked to senescence mechanisms. Novel approach on CD38, epitope-related (3 patents filed), to (1) resolve inflammation and (2) protect cells and tissues from damages. Differentiation from existing CD38-compounds strongly established.

Companion biomarkers for precision medicine.

Products to be positioned as background treatments (sporadic and familial forms), to be possibly combined with gene therapies or others.

2 programs to be partnered:

- NC-SID: mAb for auto-immune, metabolic diseases, CSS
- NC-B8: for CNS

Expertise and Technological Skills

Drug development,

Novel approach on CD38, epitope dependent --> platform on CD38 mAbs,

Companion biomarkers for precision medicine.

2 assets to be partnered:

- NC-SID: mAb for auto-immune, metabolic diseases, CSS. Sub-cutaneous administration once a week possible. Lead optimization still possible
- NC-B8: a brain penetrant humanized mAb for neuro-degenerative and neuro-muscular diseases, starting with ALS. 18 months away from the clinic (clonal selection achieved).

Ongoing Collaboration and References

Science stemming from the Pitie Salpetriere hospital laboratories (Paris, France)

Ongoing collaborations with:

- IMRM, Institut Mondor de Recherche Médicale
- ENVA, Ecole Nationale Veterinaire d'Alfort,
- CHU Tours, Université de Tours, Inserm, UMR 1253 iBRAIN

Sought Opportunities

- Out-license or co-develop NC-B8 mAb for neurodegenerative, neuromuscular, and other CNS diseases;
- Out-license or co-develop NC-SID mAb for auto-immune disorders, metabolic inflammatory diseases, acute inflammation;
- Interested in academic collaborations

Laurence BRESSAC

Title/Position:

CEO



Background

CEO and co-founder of ENCEFA in 2016

Contact/Address

Contact: laurence.bressac@encefa.com

LinkedIn Url: <https://www.linkedin.com/in/laurence-bressac-5ab7391/>

Activity

Enterome is a clinical stage company, pioneering the development of novel pharmaceuticals based on its unrivalled understanding of the gut microbiome's interaction with the immune system. Enterome is leveraging this expertise to develop clinical and pre-clinical candidates (small molecules, proteins and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases.

Enterome has two unique pipeline of highly promising drug candidates:

- OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463, is being prepared as a clinical candidate for B-cell malignancies (lymphomas and leukemias).
- EndoMimics: a new generation of biologics for inflammatory diseases (EM101), Type 2 diabetes and inflammatory bowel disease.

Expertise and Technological Skills

Enterome has developed the largest database of 20 M bacterial genes and potential proteins as well as a unique way to translate this database into drug candidates. The Company uses proprietary softwares and tools for data mining and microbiome profiling as well as prediction algorithms and machine learning to pre-select drug candidates which are screened on relevant bioassays in order to identify new generation biologics.

Ongoing Collaboration and References

Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Takeda and Abbvie in inflammatory bowel diseases and Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center, Dana Farber Institute and Bioaster in immuno-oncology.

Sought Opportunities

Enterome aims at partnering some of the hits of its EndoMimics platform, i.e. microbiome-derived effectors in the field of inflammatory and/or metabolic diseases. Enterome owns a unique library of 20M microbiome proteins that can be screen on relevant bioassays to identify new generation biologics.

Grégoire Chevalier

Title/Position:

Scientific Affairs Manager



Background

Grégoire Chevalier serves as Scientific Affairs Manager at Enterome since 2019.

Prior to joining Enterome, Dr. Chevalier served as Senior Scientific Officer for the management of Institut Pasteur from 2016 to 2017. He also served as Associate Researcher from 2017 to 2019 and Postdoctoral Researcher from 2012 to 2016 in the group of Pr. Gerard Eberl, Institut Pasteur, leading projects in the field of microbiome-host crosstalk, focusing on immunity and neuro-immune interactions.

Dr Chevalier holds a PhD in Immunology and Infectious Diseases and an Engineer Degree in Agronomy & Biotechnology.

Contact/Address

Contact: gchevalier@enterome.com

LinkedIn Url: <https://www.linkedin.com/in/gregoire-chevalier-75a4729/>

Pierre Belichard

Title/Position:

CEO



Background

Pierre Belichard has served as Enterome's Chief Executive Officer and as a member of the company's Board of Directors since 2011.

Dr. Belichard is a serial entrepreneur with more than 25 years' experience in the biopharmaceutical industry. Prior to founding Enterome, He served as Vice President of Mergers and Acquisitions and Business Development at Sanofi Ophthalmology from 2009 to 2011. Dr. Belichard was the Founder of Fovea Pharmaceuticals SA., which was acquired by Sanofi in 2009, and served as its Chief Operating Officer from 2005 to 2009. From 2002 to 2004, Dr. Belichard served as Vice President of Business Development at UroGene, S.A., a company acquired by Pierre Fabre in 2004. From 2000 to 2002, he served as head of European commercial operations at Ethypharm S.A.

Dr. Belichard holds a Pharm.D. from Grenoble Faculty of Medicine and Pharmacy, Ph.D. from University Pierre and Marie Curie and an M.B.A. from INSEAD.

Contact/Address

Contact: pbelichard@enterome.com

LinkedIn Url: <https://www.linkedin.com/in/belichard-pierre-5532523/>

Rachel Morra

Title/Position:

Senior Business Development and Alliance
Manager



Background

Rachel Morra has served as BD and Alliance Manager at Enterome since 2013.

From 2009 to 2013, Dr. Morra worked at Genomic Vision, serving first as International Products Manager then as Europe Project Leader. From 2004 to 2009 she was Research Scientist at Biopredictive where from 2008 she also occupied Marketing functions.

Dr. Morra holds a Ph.D. in Pathophysiology from Pierre and Marie Curie University.

Contact/Address

Contact: rmorra@enterome.com

LinkedIn Url: <https://www.linkedin.com/in/rachel-morra-phd-85454013/>

Activity

At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with a specific focus on inflammatory bowel diseases (IBD).

Expertise and Technological Skills

We have developed unique skills to rationally select, control and manufacture extremely-oxygen-sensitive commensal bacteria, leveraging our in-house pilot manufacturing unit. We have also gained unique regulatory know-how to develop these products as drug candidates.

Ongoing Collaboration and References

Ongoing academic collaboration with INRAe to develop new analytical tools for Live Biotherapeutics

Sought Opportunities

We are seeking to set-up research collaborations with industrial partners to evaluate our lead candidate EXL01 (*F. prausnitzii*) in combination with existing treatments, or in monotherapy, in various indications ranging from inflammatory bowel diseases, psoriasis to immuno-oncology.

Benjamin Hadida

Title/Position:

CEO & Co-founder



Background

Co-founded Exeliom Biosciences in December 2016. He is an entrepreneur who developed a wide range of skills in various industries such as investment banking (UBS), venture capital (Pacific Channel), pharmaceutical regulatory affairs (Amgen), biotech operations and even applied research at the Vision Institute in Paris.

Benjamin has a master's degree in management from ESSEC Business School (after Classes Prépas) and a master's degree in Molecular and Cellular Biology from Sorbonne University.

Contact/Address

Contact: bhadida@exeliombio.com

LinkedIn Url: <https://www.linkedin.com/in/benjaminhadida/>

Harry Sokol (Professor)

Title/Position:

Co-founder & Medical Advisor



Background

Co-founder of exeliom biosciences

Professor at the Gastroenterology department of the Saint Antoine Hospital, Paris, France

Head of the Gut Microbiome laboratory at Sorbonne University.

Internationally renowned expert in Inflammatory Bowel Disease and gut microbiome with over 200 publications in these fields.

Involved in translational research and current president of the French group of Faecal Microbiota Transplantation.

His research about the commensal bacterium *Faecalibacterium prausnitzii* led to the foundation of the company

Contact/Address

Contact: harry.sokol@gmail.com

LinkedIn Url: <https://www.linkedin.com/in/harry-sokol/>

Mathilde Antoine

Title/Position:

Operations Manager



Background

Graduated from the renowned Master in Management of the French business school, HEC.

Specialized in entrepreneurship.

Several experiences in start-up development in the field of biotechnology.

Mathilde also accompanied start-ups in the health sector within the Agoranov incubator before joining Exeliom Biosciences in 2018.

She is responsible for the day-to-day operational functions of Exeliom Biosciences

Contact/Address

Contact: mantoine@exeliombio.com

LinkedIn Url: <https://www.linkedin.com/in/mathildeantoine01/>

Location: Lille

Startup Size: Staff : 6 pers

Activity

We offer an original Treg molecular signature to assess compounds on the immune system . Our qPCR test, based on the expression of around 100 genes, determines the impact of a molecule on Tregs and their microenvironment in a single test performed either on isolated Tregs or easily on BPMCs.

Expertise and Technological Skills

Our team has a huge expertise in the field of immuno-oncology, regulatory T cells, oncolytic viruses, novel therapeutic antibody discovery.

Ex-vivo and in-vivo assessment of compounds on the immune system and Tregs to better predict clinical trials results, side effects and patient outcome.

Ongoing Collaboration and References

We have industrial collaborations with R&D of Miltenyi Biotec for Technology and methodology optimization, with Eurogentec for the primer design and the Kit development, with Soladis for the Mathematic algorithm of the Treg signature and with ONCOTHA1 for biostatistical Investigation.

Sought Opportunities

We are looking for academic, CRO or industrial partners interested to challenge their compounds against our Treg Molecular Signature.

We aim to meet with potential partners for industrialization (qPCR test, Software Saas for interpretation of the results and/or for distribution.

Clara MILHEM

Title/Position:

Research Engineer, PhD student CIFRE



Background

Contact/Address

Contact: clara.milhem@immune-insight.com

LinkedIn Url: <https://www.linkedin.com/in/clara-milhem-122434a4/>

Nadira DELHEM

Title/Position:

CSO, Co-founder, PhD, HDR



Background

Pr. Nadira Delhem is a Professor of immunology at the university of Lille and Laboratory Head (IPIC-OncoTHAI – INSERM). Winner of the prestigious Matwin award for developing a novel Galectin 9 checkpoint inhibitor “Galimab”.

Co-founder and CSO of Immune Insight, she has more than 20 years of experience in the fields of regulatory T cells, immune-oncology and therapeutic antibody design.

Contact/Address

Contact: nadira.delhem@ibl.cnrs.fr

LinkedIn Url: <https://www.linkedin.com/in/nadira-delhem-63603312b/>

Olivier MORALES

Title/Position:

Senior Scientific Consultant, Co-founder, PhD,
HRD



Background

Dr. Olivier Moralès, a researcher in the IPIC team (OncoTHAI-INSERM) and assistant professor at the CNRS for more than 17 years. Co-founder of Immune insightT, he also has an extended expertise in oncolytic viruses, immune-oncology, novel therapeutic antibody discovery and translational research.

Contact/Address

Contact: olivier.morales@ibl.cnrs.fr

LinkedIn Url: <https://www.linkedin.com/in/olivier-morales-67a16554/>

Sarah RENAUD

Title/Position:

Key Accounts Scientific Manager



Background

Dr. Sarah Renaud completed her PhD at the Pasteur Institute in Lille and is specialized in immune-oncology, notably in the role of dendritic cells and regulatory T cells in cancer.

Contact/Address

Contact: sarah.renaud@immune-insight.com

LinkedIn Url: <https://www.linkedin.com/in/sarah-renaud-phd-2108bb119/>

Thierry de CATHEU

Title/Position:

CEO/ Business Developer



Background

CEO @ Immune insight since March 2019.

More Than 30 years in the life science industry at different managing positions in big groups (Johnson & Johnson, Smith+Nephew, Sorin Biomedica, Cochlear) and in start-up including other CEO's Positions. strategic advisor and board member of several biotech and medtech companies.

Founder and CEO of Biotech Agora

Contact/Address

Contact: decatheu@immune-insight.com

LinkedIn Url: <https://www.linkedin.com/in/thierry-de-catheu-5773211a/>

Location: Paris/Nancy FRANCE

Startup Size: 17 employees

Activity

Inotrem is a clinical stage French biotechnology company focusing on the control of immune response in both acute and chronic inflammatory diseases.

Inotrem has developed its technology around the control of the amplification loop of the TREM-1 pathway in order to tame excessive immune responses initially in certain conditions in critical care, and more recently in chronic conditions. The other key strategic feature of Inotrem is a personalized medicine approach which use soluble TREM-1 as a mechanism-based biomarker to select the patients more likely to benefit from the treatment.

Inotrem lead product is a peptide, nangiobotide, currently in the clinic in both septic shock in a large phase II clinical trial and in severe forms of COVID-19 (phase II).

In parallel, Inotrem is leading a broad monoclonal antibody program to be proposed in chronic conditions

Expertise and Technological Skills

Scientific leadership in immunology, infectious diseases and innate immunity particularly the TREM-1 pathway

Broad and deep expertise in translational research and development

Multi-talented senior team with successful track record in drug development

Ongoing Collaboration and References

- Based on a mechanism based biomarker (soluble TREM-1) collaboration with Roche Diagnostics to develop a companion diagnostic assay to select patients more likely to benefit from treatment

- Collaboration with a global network of top tier critical care investigational centers

Sought Opportunities

jean-jacques garaud

Title/Position:

CEO



Background

Dr. Jean-Jacques Garaud is a senior executive with a broad international experience in Research and Development in the pharmaceutical industry. Dr. Garaud was most recently Head of Pharma Research and Early Development at Roche (2010 to 2012) and prior to that Head of Development and Chief Medical Officer at Roche (2007 to 2010). He previously held other senior positions with Schering-Plough in the USA (1991 to 2001) and Novartis in the USA and Switzerland (2001 to 2007). He is known for his leading role in the development of Interferon alpha, ribavirin and PEG-interferon in hepatitis C in the 90s and his contributions in building the new Roche R&D organization as well as and implementing Personalized Health Care at Roche.

Over the last few years he has contributed to the creation of 4 different biotechs in France and is involved in knowledge management to support early projects to mature into an industrial proposition. He has been the CEO and the co-founder of Inotrem since 2013.

Contact/Address

Contact: jjg@inotrem.com

LinkedIn Url: <https://www.linkedin.com/in/jean-jacques-garaud-97055a54/>



Location: Paris

Startup Size:

Activity

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues.

Expertise and Technological Skills

By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products - NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases.

Ongoing Collaboration and References

Sought Opportunities

At this stage LiMM is looking for collaborations and/or equity

Covadonga Pañeda

Title/Position:

Director of R&D



Background

Contact/Address

Contact: cp@limmtx.com

LinkedIn Url: <https://es.linkedin.com/in/covadonga-pa%C3%B1eda-49383711>

David Braga Malta

Title/Position:

Founder CEO



Background

Contact/Address

Contact: dbm@limmtx.com

LinkedIn Url: <https://www.linkedin.com/in/davidbragamalta/>

Jacques Mizrahi

Title/Position:

Chairman



Background

Contact/Address

Contact:

LinkedIn Url: <https://www.linkedin.com/in/jacques-mizrahi-7b464a14/>



Location: Lyon, France

Startup Size: 35

Activity

MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating cancer and graft-versus-host disease (GvHD), MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients and a Phase 2 clinical trial in acute GvHD is completed (results expected 1Q 2021). Additionally, preclinical programs target solid tumors in combination with immuno-therapy. Supporting the development and expansion of our pipeline, our discovery and analysis platform, GutPrint® enables to evaluate drug candidates, determine novel disease targets and identify biomarkers. Our Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing process to safely deliver the full diversity of the microbiome, in liquid and oral forms.

Expertise and Technological Skills

MaaT Pharma's products, Microbiome Ecosystem Therapies, are full-ecosystem, high-diversity, high-richness products aiming to restore the immune homeostasis in indications with high unmet need. Our expertise extends to both native-derived, pooled products, for the treatment of aGvHD and a new generation of fermented full-ecosystem MET targeting solid cancer indications. We also established relationships with regulators to spearhead microbiome treatment integration into clinical practice.

Ongoing Collaboration and References

MaaT Pharma is involved in multiples partnerships and collaborations focused on developing novel microbiome-based therapies, including with INRAE, Institut Gustave Roussy, APHP, Biocodex, Bioaster, Université Clermont Auvergne and Biofortis. MaaT Pharma also benefits from the commitment of world-leading scientists in our domains.


Sought Opportunities

MaaT Pharma is looking for industry partners to support late-stage development and commercialization of its assets, as well as academic partners interested in exploring the relationship between the microbiome and the immune system in our indications of interest.

Hervé Affagard

Title/Position:

CEO



Background

Hervé Affagard is an entrepreneur specialized in the healthcare sector. He founded MaaT Pharma in late 2014 together with Onco-hematologist Prof. Mohammad Mohty and Microbiologist Dr. Joël Doré, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma's development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. Today, MaaT Pharma is a patient-centric, oncology-focused microbiome company with 2 full-ecosystem live biotherapeutic programs in clinical development, 90 patients treated to date in 3 indications, and a total of €38 million raised in dilutive and non-dilutive financing, relying on a diverse, committed 30-people team with expertise ranging from artificial intelligence to microbiology, immunology and oncology. Hervé is also a board member for the French biotech industry association, FranceBiotech. He is an engineer by training and holds an MBA from EM Lyon Business School.

Contact/Address

Contact: haffagard@maat-pharma.com

LinkedIn Url: <https://www.linkedin.com/in/haffagard/>

Savita Bernal

Title/Position:

Chief Business Officer



Background

Savita joined MaaT Pharma in May 2020 as Chief Business Officer. She was previously Director of Strategic Marketing and Corporate Communications, Business Development at biopharmaceutical company ADOCIA. Before this, she was Business Development Manager at e(ye)BRAIN, a medical device company that provided assistance in diagnosing neurological and psychiatric diseases and worked as a Consultant for the Healthcare Industry at E&Y. She holds a PhD in Cognitive Neuroscience and is a graduate of Ecole Normale Supérieure de Lyon and HEC Paris Business School.

Contact/Address

Contact: sbernal@maat-pharma.com

LinkedIn Url: <https://www.linkedin.com/in/savita-bernal-5173502/>

Activity

MEDSENIC is a late stage biopharma specialized in the development of medications for autoimmune diseases. MEDSENIC currently develops a therapeutic pipeline for orphan and other diseases in the field of inflammation and autoimmunity.

Our development stage is now Phase 2 and 3 clinical studies at the international level, with convincing positive preclinical and clinical Proofs of Concept, allowing confirmatory trials to firmly establish both safety and efficacy of the treatment regimens.

Expertise and Technological Skills

Medsenic is now characterized by:

- A robust efficiency to deliver original preclinical and clinical data
- A portfolio of drugs (MCS222) in oral or IV forms under patent protection
- An experienced management team, supported by a strong Scientific Advisory Board and external partners

Ongoing Collaboration and References

- with public and private laboratories expert in animal models, especially using mice, either genetically modified or pharmacologically treated
- with experienced partners in manufacturing the INDs of the program MCS222
- with CROs for the follow up and monitoring of the Phase 2 and 3 studies

Sought Opportunities

Search for a financial/ biopharma partner to start a pivotal Phase 2-3 clinical trial for the acute respiratory distress syndrome in COVID 19 .

François RIEGER

Title/Position:

CEO / CSO - Founder



Background

Contact/Address

Contact: fr@medsenic.org

LinkedIn Url: [linkedin.com/in/francois-rieger-a3413227](https://www.linkedin.com/in/francois-rieger-a3413227)

Véronique Pomi

Title/Position:

COO - Co-founder



Background

Contact/Address

Contact: veronique.pomi@medsenic.com

LinkedIn Url: [linkedin.com/in/véronique-pomi-041b377b](https://www.linkedin.com/in/véronique-pomi-041b377b)

Location: 100 Avenue de Suffren, 75015 Paris

Startup Size:

Activity

OSE is a Clinical stage biotechnology company focused developing and partnering therapies to control the immune system for immuno-oncology, autoimmune diseases and inflammation. OSE-Immunotherapeutics has a balanced clinical and preclinical portfolio of products with a diversified risk profile.

Expertise and Technological Skills

The company has the expertise to develop agonist or antagonist monoclonal antibodies, to fight cancer and autoimmune diseases. With its Memopi® epitope (neo-epitope) optimization technology, we have also the expertise to increase the memory immune response of T lymphocytes against specific antigens.

Ongoing Collaboration and References

- OSE-127, anti-IL7R is partnered with Servier. Initiation of Two Phase 2 studies in Q4 2020: in ulcerative colitis and Sjögren's syndrome.
- BI 765063 (anti-SIRPa) is partnered with Boehringer Ingelheim; this checkpoint inhibitor is currently under Phase 1 clinical trial in advanced solid tumor

Sought Opportunities

OSE has a dynamic partnership business model based on innovative products. We are interested to discuss potential collaborations. OSE-Immunotherapeutics actively seeks international partners for out-Licensing of compounds at all stages of clinical development and co-development of drug products.

Jean-Jacques Mention

Title/Position:

PhD in Immunology / Head of Scientific Business Development



Background

EDUCATION

2004 - Ph.D. in Immunology. Paris V University René Descartes, Hôpital Necker-Enfants-Malades

2000 - Master's degree (DEA) « Biology and Pathology of epithelium ». Paris University, Hôpital Bichat

PROFESSIONAL EXPERIENCE

OSE-Immunotherapeutics, Clinical Stage Biotechnology Company, Paris & Nantes

2020 - Head of Scientific Business development (Immunotherapy IO & AID)

genOway, Biotechnology Company, Lyon & Paris

2019 - Head of Business development on humanized mouse model & Scientific Consulting

AXENIS, Biotechnology Company, specialized in Humanized mouse models, Paris

2015 - Director of Business development & Scientific Consultant

- CRO activity and production of immunodeficient mice and Humanized mouse models

Institut Pasteur, Paris

2011-2014 - Research scientist in virology (Pr. Olivier Schwartz's Lab)

To identify and characterize cellular proteins mediating Chikungunya virus entry

2008-2010 - Research scientist in immunology (Pr. James DiSanto's Lab)

Development of a new humanized mouse models as a Tool for fundamental, clinical, therapeutic and pharmaceutical research. (lymphoid and myeloid compartments)

King's College, London

2005-2008 - Research scientist in mucosal immunology (Pr. Adrian Hayday's Lab)

Selective regulation in mouse thymus and skin of an intraepithelial T lymphocyte repertoire (CD4⁺ T cell) by a gene down-regulated in carcinogenesis.

Hôpital Necker-Enfants-Malades, Paris

1999-2004 - Young Research scientist in mucosal immunology (Dr. Nadine Cerf-Bensussan's Lab)

Role of interleukine-15 in the T lymphocyte-epithelial interactions in coeliac Disease (Gluten intolerance)

University of Versailles Saint-Quentin-en-Yvelines

2011-2013 - Teacher in Biochemistry and Enzymology

HONORS / PATENT and PUBLICATIONS

2011 - PATENT : Dendritic cell-boosted humanized immune system mice. Patent No US2010029800

2008 - Grant challenge N°4 from Bill & Melinda Gates foundation for humanized immune system mice

2003 - Honor from SNFGE (Société Nationale Française de Gastroentérologie). Paris

2001 - Honor from Danone Institute: « Prix Alimentation et Santé », Paris

2003 - 2016 - 13 accepted publications, 1 in preparation and 1 book chapter

Contact/Address

Contact: jean-jacques.mention@ose-immuno.com

LinkedIn Url: <https://www.linkedin.com/in/jean-jacques-a-p-mention-54139529/>

Location: Paris

Startup Size:

Activity

Par'Immune is a clinical stage biopharmaceutical company founded in 2017. Building upon 20 years of academic research & clinical activities around the parasite-derived P28GST protein, Par'Immune aims to further develop innovative first-in-class medicines against aggressive inflammatory autoimmune disorders. Primary focus will be on mild-to-moderate Ulcerative Colitis. With a Phase II trial starting in 2021, we will offer our investors an exit through trade-sale or IPO as early as 2024

Expertise and Technological Skills

Chief Executive Officer, Co-Founder – Dr. Abderrahim Lachgar has 20+ years of experience at executive positions in the biotech start up arena. Expert with immunotherapeutic strategies, he led several international clinical trials in multimillion VC backed start-ups such as Invectys.

Chief Scientific Officer, Co-Founder – Prof. Monique Capron is Emeritus Professor of Immunology at the University of Lille, France and former President of INSERM's board of directors.

Ongoing Collaboration and References

World-renowned clinical specialists of IBD joined our Scientific and Clinical Advisory Board:

Pr. J.F. Colombel, M.D., Ph.D. is Head of the Center of Inflammatory Diseases of the Intestine at Mount Sinai New York. He is ranked 4th UC expert worldwide and is P28GST patent's co-inventor.

Pr. B. Feagan, M.D., Ph.D, is Robarts's CRO co-founder and has been the principal investigator (PI) on numerous large-scale clinical trials of IBD therapies. He is ranked 5th UC expert worldwide.

Sought Opportunities

Par'Immune's business model is the clinical development of our product as far as obtaining Proof of Concept of its human efficacy in Phase II. Par'Immune will then initiate financial and industrial partnership agreements with large pharmaceutical companies

Abderrahim Lachgar

Title/Position:

Chief Executive Officer, Co-Founder



Background

Chief Executive Officer, Co-Founder – Dr. Abderrahim Lachgar has 20+ years of experience at executive positions in the biotech start up arena. Expert with immunotherapeutic strategies, he led several international clinical trials in multimillion VC backed start-ups such as Invectys.

Contact/Address

Contact: a.lachgar@parimmune.com

LinkedIn Url: <https://www.linkedin.com/in/abderrahim-lachgar-22a00911/>

Monique Capron

Title/Position:

Chief Scientific Officer, Co-Founder

Background

Prof. Monique Capron is Emeritus Professor of Immunology at the University of Lille, France and former President of INSERM's board of directors.

Contact/Address

Contact: m.capron@parimmune.com

LinkedIn Url:

Location: PARIS

Startup Size: 9 employees

Activity

Peptinov is a biotech based in Cochin Hospital (Paris), which develops an innovative therapeutic strategy: peptide-based active immunotherapy targeting self-proteins (which is a form of immuno-modulation), for the treatment of chronic inflammatory diseases, notably with low-grade inflammation.

Expertise and Technological Skills

Peptinov has a unique bioinformatics expertise and know-how. Immunogenic peptide conjugates are designed through its development platform. These conjugates induce the production of antibodies targeting self-proteins to inhibit the negative effects of their overproduction.

Ongoing Collaboration and References

Peptinov is located in Cochin Hospital (Paris), which is a reference institution in the field of rheumatology. Peptinov benefits from the support of a Medical & Scientific Board with renowned Key Opinion Leaders in the field rheumatology. Peptinov's technology originates from Cnam.

Sought Opportunities

Peptinov is looking for financial and industrial partners in order to carry out its next steps of clinical development, in the field of low-grade inflammation and osteoarthritis.

Hervé DO

Title/Position:

CFO



Background

Hervé Do holds a MSc in Chemistry from Chimie-ParisTech and a PhD in Biology from Pierre & Marie Curie University (Paris 6).

He founded and has managed his own services company (a 12-employee company) that he exited in 2009. He joined Peptinov at its inception in 2009 and is in charge of grant applications, business-development and finances. He has a dual scientific and business experience, which is a important asset for Peptinov. Hervé has successfully obtained public funding (national grants, R&D tax rebates & interest-free loans) for Peptinov for a sum total of €5m. Out of these €5m, he co-managed funded scientific projects (totalling €1.3m in grants).

Contact/Address

Contact: herve.do@peptinov.fr

LinkedIn Url: <https://www.linkedin.com/in/herve-do-41b23b3/>

René AZOULAI

Title/Position:

CEO



Background

René Azoulai has been the CEO of Peptinov since Jan 2018. He is a graduate engineer from École Polytechnique. He has more than 20 years of experience managing business units and innovative strategies in the fields of IT services and in the air transport industry, at senior executive level and on a worldwide scale. He has also been in charge of M&As and of an international joint venture operation.

René has been a significant investor in Peptinov since its inception, as well as a member of its strategic board. Peptinov greatly benefits from his managerial, strategic and business development experience during its current expansion phase, including on an international basis.

Contact/Address

Contact: rene.azoulai@peptinov.fr

LinkedIn Url: <https://www.linkedin.com/in/ren%C3%A9-azoulai-9175aa6/>

Location: Paris

Startup Size:

Activity

Stimulab (www.stimulab.fr), independent private company, is involved in the therapeutic education for patient and health education program by digitalizing programs and integrating them into a dedicated digital platform. Stimulab creates digital therapeutics for patients with chronic diseases.

Expertise and Technological Skills

Digital therapeutic education, e-health engineering and digital platform for e-health.

Ongoing Collaboration and References

We help hospitals (AP-HP, Unicancer, etc...) and Assurance Maladie in France to use digital tools to engage patients for their quality of life. Stimulab is working with Lupus Plus, the major patient representative organization for Systemic Lupus in France and the National Lupus Reference Center.

Sought Opportunities

Partnership about digital therapeutic education for rare diseases (such as Lupus).

Brochard Marc-Antoine

Title/Position:

CEO



Background

Contact/Address

Contact: marc-antoine@stimulab.fr

LinkedIn Url: <https://fr.linkedin.com/in/marc-antoine-brochard-4224871b>

Morant Antoine

Title/Position:

Partnership

Background

Contact/Address

Contact: antoine@stimulab.fr

LinkedIn Url: <https://fr.linkedin.com/in/antoine-morant-ba789210a>

MARCH 16-17 2021

IMMUNOLOGY & INFLAMMATORY DISORDERS

100% DIGITAL EXPERIENCE

Contact

contact@hybridays.com

WWW.HYBRIDAYS.COM